Practical management of antineoplastic-induced nausea and vomiting from antibody–drug conjugates: Insights from a Canadian expert panel
Journal of Oncology Pharmacy Practice
Published online on April 16, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
ObjectiveTrastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) that are associated with clinically significant antineoplastic-induced nausea and vomiting (AINV), for which prophylaxis and management strategies ...
ObjectiveTrastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) that are associated with clinically significant antineoplastic-induced nausea and vomiting (AINV), for which prophylaxis and management strategies ...